Screening for cerebrovascular disease in microcephalic osteodysplastic primordial dwarfism type II (MOPD II): an evidence-based proposal

Pediatr Neurol. 2013 Apr;48(4):294-8. doi: 10.1016/j.pediatrneurol.2012.12.010.

Abstract

Microcephalic osteodysplastic primordial dwarfism type II (OMIM 210720) is a rare autosomal recessive condition frequently associated with early-onset cerebrovascular disease. Presymptomatic detection and intervention could prevent the adverse consequences associated with this. We reviewed published cases of microcephalic osteodysplastic primordial dwarfism type II to ascertain prevalence and characteristics of cerebrovascular disease and use these data to propose an evidence-based approach to cerebrovascular screening. Of 147 cases identified, 47 had cerebrovascular disease (32%), including occlusive arteriopathy (including moyamoya) and cerebral aneurysmal disease. Occlusive disease occurred in younger individuals, and progression can be both rapid and clinically silent. A reasonable screening approach would be magnetic resonance imaging and angiography of the cervical and intracranial circulation at diagnosis, repeated at yearly intervals until 10 years, and every 2 years thereafter, unless clinical concerns occur earlier. At present it would appear that this needs to be life-long. Families and professionals should be alerted to the potential significance of neurologic symptoms and measures should be taken to maintain good vascular health in affected individuals.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Cerebrovascular Disorders / diagnosis*
  • Cerebrovascular Disorders / epidemiology*
  • Dwarfism / diagnosis*
  • Dwarfism / epidemiology*
  • Evidence-Based Medicine / methods*
  • Fetal Growth Retardation / diagnosis*
  • Fetal Growth Retardation / epidemiology*
  • Humans
  • Mass Screening / methods*
  • Microcephaly / diagnosis*
  • Microcephaly / epidemiology*

Supplementary concepts

  • Microcephalic osteodysplastic primordial dwarfism, type 3